罗格列酮对2型糖尿病患者血清TNF-α的影响及其与胰岛素抵抗的关系

目的：了解罗格列酮治疗后2型糖尿病患者血清TNF-α水平的改变以及其与胰岛素抵抗的关系。方法：用放射免疫法检测27例2型糖尿病患者经罗格列酮治疗12周前后血清TNF-α水平、空腹血清胰岛素（FBINS）、空腹血糖（FBS）、血脂、体重，计算稳态模型评价的胰岛素抵抗指数（HOMA-IR）。结果： 2型糖尿病患者治疗前血清TNF-α水平明显高于正常对照组（P＜0.005）；治疗后患者血清TNF-α水平显著降低（P＜0.001）。 2型糖尿病患者血清TNF-α与甘油三脂（TG），FBS，ln(HOMA-IR)呈显著正相关，而与HDL-C呈显著负相关（r=-0.508，P＜0.05）。结论：罗格列酮治疗后可显著降低2型糖尿病患者血清TNF-α水平，并能改善患者胰岛素抵抗程度。

Effect of rosiglitazone on level of serum TNF-α and its relation with insulin resistance in type 2 diabetes mellitus

ObjectiveTo investigate the change of serum TNF-α level in type 2 diabetes mellitus after treating with rosiglitazone, and the relationship between TNF-α and insulin resistance. MethodsThe level of serum TNF-α in 27 patients was tested by radioimmunoassay before and after treating with rosiglitazone. Free insulin, free blood sugar, TG, HDL-C and weight were measured, and HOMA-IR was calculated.  ResultsThe level of serum TNF-α in the patients was higher than that in the controls (P<0.005) and rosiglitazone could decrease the level of serum TNF-α (P<0.001).The level of serum TNF-α was positively related to serum TNF-α,TG,FBS and ln (HOMA-IR), and it was negatively related to HDL-C (r=-0.508,P<0.05).ConclusionRosiglitazone can decrease the level of serum TNF-α significantly and improve insulin resistance.